KDev Oncology AB

GliGene is an early stage biotechnology company focusing on the discovery of new drugs against cancer. The vision is to develop an effective new small molecule drug for the treatment of pancreatic cancer and other cancers where there is a great medical need. The unique combination of the co-founders of GliGene Prof Toftgård’s and colleagues’ world class research in the Gli and Hedgehog area with Karolinska Development’s pharmaceutical development skills gives GliGene a unique opportunity to find, develop and commercialize new anticancer drugs.